Hem › Njurcancer (renalcelskarcinom) › Pennsylvania › Hazleton
Kliniska studier för Njurcancer (renalcelskarcinom) i Hazleton, PA
4 studier för Njurcancer (renalcelskarcinom) söker deltagare vid platser i och runt Hazleton (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekryterarObservationsstudieFriska volontärer välkomna
- Lehigh Valley Hospital-Hazleton, Hazleton
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekryterarFas 2
- Lehigh Valley Hospital-Hazleton, Hazleton
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekryterarFas 2
- Geisinger Medical Center-Cancer Center Hazleton, Hazleton
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekryterarFas 3
- Geisinger Medical Center-Cancer Center Hazleton, Hazleton
- Lehigh Valley Hospital-Hazleton, Hazleton
Njurcancer (renalcelskarcinom)-studier i andra städer
- Houston, TX35 studier
- New York City, NY27 studier
- Nashville, TN23 studier
- Dallas, TX23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Boston, MA16 studier
- Baldwin Park, CA16 studier
- Pittsburgh, PA15 studier
- Philadelphia, PA15 studier
- Queens, NY15 studier
- Rochester, MN14 studier
Andra studier i Hazleton
- Kolorektal cancer5 studier
- Bröstcancer4 studier
- Icke-småcellig lungcancer4 studier
- Tjocktarmscancer4 studier
- Prostatacancer4 studier
- Multipelt myelom3 studier
- Cancer (alla typer)3 studier
- Rektalcancer3 studier
- Lungcancer3 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.